1
|
Kang SJ, Kim JE. Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies. Pharmaceutics 2023; 15:pharmaceutics15041246. [PMID: 37111730 PMCID: PMC10141516 DOI: 10.3390/pharmaceutics15041246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 04/09/2023] [Accepted: 04/11/2023] [Indexed: 04/29/2023] Open
Abstract
The purpose of this study is to derive an optimal drug release formulation with human clinical bioequivalence in developing a sitagliptin phosphate monohydrate-dapagliflozin propanediol hydrate fixed-dose combination (FDC) tablet as a treatment for type 2 diabetes mellitus. As a treatment for type 2 diabetes mellitus, the combined prescription of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is common. Therefore, this study simplified the number of individual drugs taken and improved drug compliance by developing FDC tablets containing sitagliptin phosphate monohydrate as a DPP-4 inhibitor and dapagliflozin propanediol hydrate as an SGLT-2 inhibitor. To derive the optimal dosage form, we prepared single-layer tablets, double-layer tablets, and dry-coated tablets and evaluated the drug control release ability, tableting manufacturability, quality, and stability. Single-layer tablets caused problems with stability and drug dissolution patterns. When the dissolution test was performed on the dry-coated tablets, a corning effect occurred, and the core tablet did not completely disintegrate. However, in the quality evaluation of the double-layer tablets, the hardness was 12-14 kilopond, the friability was 0.2%, and the disintegration was within 3 min. In addition, the stability test revealed that the double-layer tablet was stable for 9 months under room temperature storage conditions and 6 months under accelerated storage conditions. In the drug release test, only the FDC double-layer tablet showed the optimal drug release pattern that satisfied each drug release rate. In addition, the FDC double-layer tablet showed a high dissolution rate of over 80% in the form of immediate-release tablets within 30 min in a pH 6.8 dissolution solution. In the human clinical trial, we co-administered a single dose of a sitagliptin phosphate monohydrate-dapagliflozin propanediol hydrate FDC double-layered tablet and the reference drug (Forxiga®, Januvia®) in healthy adult volunteers. This study showed clinically equivalent results in the stability and pharmacodynamic characteristics between the two groups.
Collapse
Affiliation(s)
- So-Jin Kang
- Department of Pharmaceutical Engineering, Catholic University of Daegu, Hayang-Ro 13-13, Gyeongsan 38430, Republic of Korea
| | - Joo-Eun Kim
- Department of Biopharmaceutical Chemistry, School of Applied Chemistry, Kookmin University, Seoul 02707, Republic of Korea
| |
Collapse
|
2
|
Wangler J, Jansky M. Attitudes and experiences of registered diabetes specialists in using health apps for managing type 2 diabetes: results from a mixed-methods study in Germany 2021/2022. Arch Public Health 2023; 81:36. [PMID: 36882859 PMCID: PMC9990333 DOI: 10.1186/s13690-023-01051-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 02/28/2023] [Indexed: 03/09/2023] Open
Abstract
BACKGROUND Hardly any area of application for health apps is seen to be as promising as health and lifestyle support in type 2 diabetes mellitus. Research has emphasised the benefits of such mHealth apps for disease prevention, monitoring, and management, but there is still a lack of empirical data on the role that health apps play in actual type 2 diabetes care. The aim of the present study was to gain an overview of the attitudes and experiences of physicians specialising in diabetes with regard to the benefits of health apps for type 2 diabetes prevention and management. METHODS An online survey was conducted amongst all 1746 physicians at practices specialised in diabetes in Germany between September 2021 and April 2022. A total of 538 (31%) of the physicians contacted participated in the survey. In addition, qualitative interviews were conducted with 16 randomly selected resident diabetes specialists. None of the interviewees took part in the quantitative survey. RESULTS Resident diabetes specialists saw a clear benefit in type 2 diabetes-related health apps, primarily citing improvements in empowerment (73%), motivation (75%), and compliance (71%). Respondents rated self-monitoring for risk factors (88%), lifestyle-supporting (86%), and everyday routine features (82%) as especially beneficial. Physicians mainly in urban practice environments were open to apps and their use in patient care despite their potential benefit. Respondents expressed reservations and doubts on app user-friendliness in some patient groups (66%), privacy in existing apps (57%), and the legal conditions of using apps in patient care (80%). Of those surveyed, 39% felt capable of advising patients on diabetes-related apps. Most of the physicians that had already used apps in patient care saw positive effects in increased compliance (74%), earlier detection of or reduction in complications (60%), weight reduction (48%), and decreased HbA1c levels (37%). CONCLUSIONS Resident diabetes specialists saw a real-life benefit with added value from health apps for managing type 2 diabetes. Despite the favourable role that health apps may play in disease prevention and management, many physicians expressed reservations regarding usability, transparency, security, and privacy in such apps. These concerns should be addressed more intensively towards bringing about ideal conditions for integrating health apps successfully in diabetes care. This includes uniform standards governing quality, privacy, and legal conditions as binding as possible with regard to apps and their use in a clinical setting.
Collapse
Affiliation(s)
- Julian Wangler
- Center for General Medicine and Geriatrics, University Medical Center of the Johannes Gutenberg University Mainz, Am Pulverturm 13, 55131, Mainz, Germany.
| | - Michael Jansky
- Center for General Medicine and Geriatrics, University Medical Center of the Johannes Gutenberg University Mainz, Am Pulverturm 13, 55131, Mainz, Germany
| |
Collapse
|
3
|
Borgmann SO, Verket M, Gontscharuk V, Bücker B, Arnolds S, Spörkel O, Wilm S, Icks A. Diabetes-related research priorities of people with type 1 and type 2 diabetes: a cross-sectional study in Germany. Sci Rep 2022; 12:20835. [PMID: 36460748 PMCID: PMC9718826 DOI: 10.1038/s41598-022-24180-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 11/11/2022] [Indexed: 12/03/2022] Open
Abstract
To investigate (i) the importance and priorities of research objectives for people with type 1 (T1DM) and type 2 diabetes (T2DM); (ii) subgroups with specific research priorities; (iii) associated factors (e.g., sociodemographic characteristics) of the subgroups. The cross-sectional survey was conducted in 2018 using data from 869 respondents (29.0% response, 31.2% female, mean age 61.3 years, 62.7% T2DM) from a German statutory health insurance population. Diabetes-related research priorities were assessed with a questionnaire. Subgroups and associated factors were identified using latent class analysis. Three subgroups were found in T1DM: (1) high priority for the research topic 'healing diabetes' and moderate priority for the research topic 'prevention of long-term complications', (2) priorities for simplifying handling (high) and stress reduction (moderate), (3) priorities for healing diabetes (high) and simplifying handling (high). Three subgroups were found in T2DM: (1) priorities for simplifying handling (moderate), diabetes prevention (moderate) and prevention of long-term complications (moderate), (2) priorities for stress reduction (high) and diabetes prevention (moderate), (3) priorities for simplifying handling (high) and stress reduction (high). Classes differed in age and HbA1c. Knowledge about research priorities enables researchers to align their work with the needs of people with diabetes.
Collapse
Affiliation(s)
- Sandra Olivia Borgmann
- grid.429051.b0000 0004 0492 602XInstitute for Health Services Research and Health Economics, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany ,grid.411327.20000 0001 2176 9917Institute for Health Services Research and Health Economics, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany ,grid.452622.5German Center for Diabetes Research (DZD), Partner Düsseldorf, Ingolstädter Landstraße 1, 85764 München-Neuherberg, Germany
| | - Marlo Verket
- grid.452622.5German Center for Diabetes Research (DZD), Partner Düsseldorf, Ingolstädter Landstraße 1, 85764 München-Neuherberg, Germany ,grid.429051.b0000 0004 0492 602XNational Diabetes Information Center, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany ,grid.1957.a0000 0001 0728 696XPresent Address: Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Veronika Gontscharuk
- grid.429051.b0000 0004 0492 602XInstitute for Health Services Research and Health Economics, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany ,grid.411327.20000 0001 2176 9917Institute for Health Services Research and Health Economics, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany ,grid.452622.5German Center for Diabetes Research (DZD), Partner Düsseldorf, Ingolstädter Landstraße 1, 85764 München-Neuherberg, Germany
| | - Bettina Bücker
- grid.411327.20000 0001 2176 9917Institute of General Practice, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany
| | - Sabine Arnolds
- grid.418757.80000 0001 0669 446XProfil Institut für Stoffwechselforschung GmbH, Hellersbergstraße 9, 41460 Neuss, Germany
| | - Olaf Spörkel
- grid.452622.5German Center for Diabetes Research (DZD), Partner Düsseldorf, Ingolstädter Landstraße 1, 85764 München-Neuherberg, Germany ,grid.429051.b0000 0004 0492 602XNational Diabetes Information Center, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany
| | - Stefan Wilm
- grid.411327.20000 0001 2176 9917Institute of General Practice, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany
| | - Andrea Icks
- grid.429051.b0000 0004 0492 602XInstitute for Health Services Research and Health Economics, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany ,grid.411327.20000 0001 2176 9917Institute for Health Services Research and Health Economics, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany ,grid.452622.5German Center for Diabetes Research (DZD), Partner Düsseldorf, Ingolstädter Landstraße 1, 85764 München-Neuherberg, Germany
| |
Collapse
|
4
|
Wangler J, Jansky M. Bedeutung und Einsatzpotenziale von Gesundheits-Apps in der diabetologischen Versorgung – Ergebnisse einer Befragungsstudie. DIABETOL STOFFWECHS 2022. [DOI: 10.1055/a-1859-6400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
Zusammenfassung
Hintergrund Mit Blick auf Diabetes mellitus Typ 2 als lebensstilinduzierte Erkrankung wird ein großer potenzieller Nutzen in Gesundheits-Apps gesehen, die gesundheitsunterstützend bei Prävention und Monitoring oder auch der Therapie helfen sollen. Das Ziel der Studie ist es, den Anwendungshorizont, die Akzeptanz und Einstellungen sowie Erfahrungen von Ärzt*innen aus diabetologischen Schwerpunktpraxen hinsichtlich des Nutzungspotenzials von Gesundheits-Apps für Diagnostik, Therapie und Prävention bei Diabetes mellitus Typ 2 explorativ zu beleuchten.
Methodik Aufbauend auf mehreren Vorstudien wurden mittels schriftlicher Befragung zwischen März und Mai 2021 insgesamt 291 Ärzt*innen diabetologischer Schwerpunktpraxen in Rheinland-Pfalz, Hessen, Thüringen und dem Saarland anonymisiert befragt. Die Rücklaufquote beträgt 30% (N=88). Neben der deskriptiven Analyse wurde ein t-Test bei unabhängigen Stichproben durchgeführt.
Ergebnisse Die Befragten verbinden mit dem Einsatz von Apps eine wirksame Stärkung von Empowerment, Motivation und Compliance, aber auch durch Erinnerungs- und lebensstilunterstützenden Funktionen eine mögliche Effektivierung der Prävention und des Erkrankungsmanagements von Typ-2-Diabetes-Patient*innen. Gerade jüngere Ärzt*innen in städtischen Praxisumgebungen begegnen Gesundheits-Apps mit positiver Einstellung und greifen im Praxisalltag auf solche Tools zurück. Skepsis besteht auf Seiten der Befragten u.a. in Bezug auf die Anwendungsfreundlichkeit und Datensicherheit bestehender Apps sowie hinsichtlich rechtlicher Fragestellungen. Eine Mehrheit räumt ein, keinen ausreichenden Überblick über diabetologische Apps zu besitzen und traut sich eine Beratung von Patient*innen nur bedingt zu. Diejenigen Ärzt*innen, bei denen Apps schon in der Versorgung Einzug fanden, beobachten in großer Mehrzahl positive Effekte bei der Steigerung der Compliance, im schnelleren Aufdecken bzw. Verringern von Komplikationen, bei der Gewichtsreduktion sowie bei der Abnahme des HbA1c-Werts.
Diskussion Trotz der positiver Effekte, die Gesundheits-Apps für Prävention und Therapie haben können, bestehen bei vielen diabetologischen Ärzt*innen Vorbehalte hinsichtlich der Überschaubarkeit, Transparenz und Sicherheit von Apps. Diese Bedenken sollten verstärkt adressiert werden, um die richtigen Voraussetzungen für eine erfolgreiche Integration von Gesundheits-Apps in die diabetologische Versorgung zu schaffen (u.a. verbindliche Datenschutz- und Qualitätsstandards, klare Rechtslage in Bezug auf die Anwendung von Apps, Schulungen, Tools zur Übersicht und Einordnung).
Collapse
Affiliation(s)
- Julian Wangler
- Zentrum für Allgemeinmedizin und Geriatrie, Universitätsmedizin Mainz, Mainz, Germany
| | - Michael Jansky
- Zentrum für Allgemeinmedizin und Geriatrie, Universitätsmedizin Mainz, Mainz, Germany
| |
Collapse
|
5
|
Bojunga J, Friedrich-Rust M. Diabetestherapie bei fortgeschrittenen Lebererkrankungen und Leberzirrhose. DIABETOLOGE 2021. [DOI: 10.1007/s11428-021-00822-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Rupprecht B, Stöckl A. [Perioperative Management of Long-term Antidiabetic Therapy in Patients with Diabetes Mellitus]. Anasthesiol Intensivmed Notfallmed Schmerzther 2021; 56:679-690. [PMID: 34704245 DOI: 10.1055/a-1226-4733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Drug therapy, as well as diabetes technology, e.g. insulin pumps or sensor glucose measurement, have developed enormously in recent years. Their use differs according to the type of diabetes, secondary or concomitant diseases, and individual factors and target values. In the perioperative phase, diabetic patients are generally at increased risk of complications, including a derailment of glucose metabolism, an increased rate of cardiovascular events, worsening of preexisting renal insufficiency, and increased incidence of wound infections. In addition, drug class-specific side effects of antidiabetic therapy may occur. The prevalence of diabetes patients in anesthesiology is high and will continue to increase. In Germany, more than 8 million people are estimated to live with diabetes mellitus. The rate of new cases is about 600 000 per year. The distinction between type 1 and type 2 diabetes mellitus is essential. Diabetes therapy is becoming increasingly individualized; combination therapies are becoming more common. Therefore, the management of long-term medication should also be individualized. Substance-specific side effects or adverse effects, especially of oral antidiabetic agents, must be considered in the care of patients, e.g. euglycemic diabetic ketoacidosis under SGLT-2 inhibitors is a relevant problem. Insulin therapy is also evolving; knowledge of new preparations and of insulin pump therapy facilitates perioperative management. Both hypoglycemia and hyperglycemia, possibly with ketoacidosis, must be avoided. The purpose of this article is to provide an overview of the management of long-term medication in patients with diabetes mellitus.
Collapse
|
7
|
Seoudy AK, Beckmann A, Wietzke-Braun P, Settgast U, Ziegenbruch U, Türk K, Hartmann K, Brandes J, Schulte DM, Wehkamp K, Trettow M, Schreiber S, Laudes M. Tagesklinische Versorgungsstruktur zur Komplextherapie der Adipositas III°. DIABETOL STOFFWECHS 2021. [DOI: 10.1055/a-1482-8115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Zusammenfassung
Hintergrund Die konservativen Behandlungsmöglichkeiten der Adipositas III° (BMI ≥ 40 kg/m2) sind limitiert, da flächendeckend eine adäquate Versorgungsstruktur nicht vorgehalten wird. Am Universitätsklinikum Schleswig-Holstein, Campus Kiel, wurde 2018 eine Tagesklinik zur Komplextherapie der Adipositas III° eingerichtet mit Sicherung der Finanzierung durch die Kostenträger über Tagessätze gemäß Krankenhausentgeltgesetz.
Methode Von 201 Adipositaspatienten, die sich von Juni 2018 bis Mai 2020 vorstellten, wurde die Tagesklinikbehandlung analysiert und zusätzlich wurde das Körpergewicht ein Jahr später ausgewertet.
Ergebnisse Die Komplextherapie fand in wöchentlichen Behandlungseinheiten über 26 Wochen statt. 170 von 201 Patienten haben die Behandlung komplettiert, entsprechend einer Adhärenzquote von 84,6 %. Das mediane Alter betrug 46 Jahre. Die Mehrheit der Patienten war weiblichen Geschlechts (64,7 %). In der Gruppe der Responder (≥ 10 % Gewichtsreduktion) betrug die absolute Gewichtsabnahme 27,1 kg entsprechend etwa 20 %. Auch die Non-Responder (< 10 %) konnten ihr Körpergewicht um 8,8 kg reduzieren; in dieser Gruppe fand sich ein signifikant höherer Frauenanteil (81,3 % vs. 60,9 %, p = 0,039). Responder und Non-Responder unterschieden sich hinsichtlich des Bauch- und Hüftumfangs sowie der Fettmasse (p-Wert jeweils < 0,001). Am Therapieende wiesen die Responder niedrigere Triglyzerid- (p = 0,019) und HbA1c-Konzentrationen (p = 0,030) auf. Ein Jahr nach Beginn der Komplextherapie imponierte eine stabile Gewichtsreduktion in beiden Gruppen.
Schlussfolgerung Die teilstationäre Adipositas-Komplextherapie in einer internistischen Tagesklinik stellt eine effektive Methode zur anhaltenden Gewichtsreduktion von Patienten mit Adipositas III° dar.
Collapse
Affiliation(s)
| | - Alexia Beckmann
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | | | - Ute Settgast
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Ursula Ziegenbruch
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Kathrin Türk
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Katharina Hartmann
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Juliane Brandes
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | | | - Kai Wehkamp
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Marc Trettow
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Stefan Schreiber
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Matthias Laudes
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| |
Collapse
|
8
|
Motivation und Achtsamkeit. DIABETOLOGE 2021. [DOI: 10.1007/s11428-021-00805-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Becker U. Bewegungsangebote in der Praxis. DIABETOL STOFFWECHS 2021. [DOI: 10.1055/a-1304-0336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
|